Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Reduced frequency is very encouraging for patient compliance and could help those who dislike weekly injections and ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital ...